Shareholders of Ligand will receive 100% of OmniAb in a tax-free distribution.
The two transactions could raise a combined $5 billion. The US Senate passed legislation this week that could prevent some Chinese companies from listing shares in the US.
The company believes it is undervalued on Nasdaq amid rising tensions between the US and China.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
| Website: | www.ligand.com |
| Email: | investors@ligand.com |
| Main Phone: | +1 858 550-7500 |
| Address: | 3911 Sorrento Valley Boulevard |
| Address 2: | Suite 110 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NSD |
| CEO: | John L. Higgins |
| Employees: | 155 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Shareholders of Ligand will receive 100% of OmniAb in a tax-free distribution.
The two transactions could raise a combined $5 billion. The US Senate passed legislation this week that could prevent some Chinese companies from listing shares in the US.
The company believes it is undervalued on Nasdaq amid rising tensions between the US and China.
NetEase reports earnings today, and the gaming giant has multiple growing revenue streams.
The online travel giant is expected to follow Alibaba by listing closer to home.
This group has powerful secular tailwinds behind them that will likely fuel earnings growth for many years.
China is moving rapidly into the 21st century.
Here's what to look for.
Despite the bull, we may be in for some short term volatility...
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
